Conceptual Foundations of the UCSD Statin Study: A Randomized Controlled Trial Assessing the Impact of Statins on Cognition, Behavior, and Biochemistry

Archives of Internal Medicine

Volumn 164, Issue 2, 2004, Pages 153-162

  Golomb, Beatrice Alexandra ^a,b,d,e   Criqui, Michael H ^a,b   White, Halbert ^b   Dimsdale, Joel E ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SEROTONIN AGONIST; SIMVASTATIN;

AGGRESSIVENESS; BEHAVIOR DISORDER; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DRUG COST; DRUG EFFECT; DRUG MECHANISM; HEART DISEASE; HUMAN; HYPOTENSION; MAJOR DEPRESSION; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SECONDARY PREVENTION; SEROTONIN BLOOD LEVEL; SIDE EFFECT; STROKE; SUICIDAL BEHAVIOR; SUICIDE; VIOLENCE;

AGGRESSION; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHOLESTEROL; COGNITION; HUMANS; HYPERCHOLESTEROLEMIA; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS; SEROTONIN; SIMVASTATIN; UNITED STATES;

EID: 0942265627     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.2.153     Document Type: Review

References (245)

1. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1998;128:89-95.
2. Hebert P, Gaziano M, Chan K, Hennekens C. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 1997;278:313-321.
3. Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs. 2001;61:197-206.
4. Simons J. The $10 billion pill: hold the fries, please: Lipitor, the cholesterol-lowering drug, has become the best selling pharmaceutical in history: here's how Pfizer did it. Fortune. 2003;147(1):58.
5. Clark T. Pfizer braces for rivals to main drugs: Viagra, Lipitor. National Post. August 15, 2003:IN8.
6. Appleby J. Drug spending surged 17% last year: figure has nearly doubled in 4 years. USA Today. 2002:A1.
7. Pfizer reports 38% increase in net income in fourth quarter. San Diego Union Tribune. January 24, 2002:C3.
8. Brown D. Heart drug far surpasses expectations. Washington Post. 2001:A1.
9. Kendall MJ, Nuttall SL. The heart protection study: statins for all those at risk? J Clin Pharm Ther. 2002;27:1-4.
10. Haney DQ. Cholesterol drug is very secret weapon. San Diego Union Tribune. 1999:E2.
11. Dales MJM. Statination. Intern Med News. February 1, 2000:55.
12. SoRelle R. Baycol withdrawn from market. Circulation. 2001;104:E9015-E9016.
13. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567-572.
14. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-585.
15. Gaist D, Jeppesen M, Andersen LA, Garcia Rodriguez J, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology. 2002;58:1333-1337.
16. Donaghy M. Assessing the risk of drug-induced neurological disorders. Neurology. 2002;58:1321-1322.
17. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446-1452.
18. Scott HD, Laake K. Statins for the reduction of risk of Alzheimer's disease. Cochrane Database Syst Rev. 2001;3:CD003160.
19. Lesser G, Kandiah K, Libow LS, et al. Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2001;12:138-145.
20. Lehtonen A, Luutonen S. High-density lipoprotein cholesterol levels of very old people in the diagnosis of dementia. Age Ageing. 1986;15:267-270.
21. Wehr H, Parnowski T, Puzynski S, et al. Apolipoprotein E genotype and lipid and lipoprotein levels in dementia. Dement Geriatr Cogn Disord. 2000;11:70-73.
22. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 2001;49:281-287.
23. Lefer DJ. Statins as potent antiinflammatory drugs. Circulation. 2002;106:2041-2042.
24. Dobrucki LW, Kalinowski L, Dobrucki IT, Malinski T. Statin-stimulated nitric oxide release from endothelium. Med Sci Monit. 2001;7:622-627.
25. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001;32:980-986.
26. Sessa WC. Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins? Trends Mol Med. 2001;7:189-191.
27. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-1443.
28. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med. 1995;155:50-55.
29. McDowell I. Alzheimer's disease: insights from epidemiology. Aging (Milano). 2001;13:143-162.
30. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life: findings from the Nun Study. JAMA. 1996;275:528-532.
31. Prince M, Lovestone S, Cervilla J, et al. The association between APOE and dementia does not seem to be mediated by vascular factors. Neurology. 2000;54:397-402.
32. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001;12:105-112.
33. Khan AA. Cholesterol metabolism in the myelin of rat brain. Experientia. 1968;24:814-815.
34. Spohn M, Davison AN. Cholesterol metabolism in myelin and other subcellular fractions of rat brain. J Lipid Res. 1972;13:563-570.
35. Koenig SH. Cholesterol of myelin is the determinant of gray-white contrast in MRI of brain. Magn Reson Med. 1991;20:285-291.
36. Jurevics H, Morell P. Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem. 1995;64:895-901.
37. Cintra A, Lindberg J, Chadi G, et al. Basic fibroblast growth factor and steroid receptors in the aging hippocampus of the brown Norway rat: immunocytochemical analysis in combination with stereology. Neurochem Int. 1994;25:39-45.
38. McEwen BS, Cameron H, Chao HM, et al. Resolving a mystery: progress in understanding the function of adrenal steroid receptors in hippocampus. Prog Brain Res. 1994;100:149-155.
39. Cremel G, Filliol D, Jancsik V, Rendon A. Cholesterol distribution in rat liver and brain mitochondria as determined by stopped-flow kinetics with filipin. Arch Biochem Biophys. 1990;278:142-147.
40. Stevenson PM, Scott CD, Galas ET. Interactions between ATP and cholesterol side-chain cleavage in mitochondria isolated from superovulated rat ovaries. Int J Biochem. 1985;17:1357-1362.
41. Vol'skii GG. Binding of glucocorticoid hormones and cholesterol to rat brain and liver mitochondria [in Russian]. Biokhimiia. 1982;47:647-652.
42. Speranza ML, Gaiti A, De Medio GE, Montanini I, Porcellati G. The inhibition of mitochondrial respiration by β-benzal butyric acid and the possible relationship to cholesterol biosynthesis. Biochem Pharmacol. 1970;19:2737-2743.
43. Pedersen HS, Mortensen SA, Rohde M, et al. High serum coenzyme Q10, positively correlated with age, selenium and cholesterol, in Inuit of Greenland: a pilot study. Biofactors. 1999;9:319-323.
44. Willis RA, Folkers K, Tucker JL, Ye CQ, Xia LJ, Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci U S A. 1990;87:8928-8930.
45. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996;42:333-337.
46. Barbiroli B, Frassineti C, Martinelli P, et al. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies: an in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell Mol Biol (Noisy-le-grand). 1997;43:741-749.
47. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies: short-term double-blind, crossover study. Eur Neurol. 1997;37:212-218.
48. Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology. 1997;48:1238-1243.
49. Fosslien E. Mitochondrial medicine-molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci. 2001;31:25-67.
50. Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J Neurol Sci. 1998;156:41-46.
51. Blasiak J, Walter Z. Protective action of cholesterol against changes in membrane fluidity induced by malathion. Acta Biochim Pol. 1992;39:49-52.
52. Blasiak J. Protective action of cholesterol against changes in membrane fluidity induced by methylparathion. Acta Biochim Pol. 1993;40:35-38.
53. Tsujita M, Ichikawa Y. Substrate-binding region of cytochrome P-450SCC (P-450 XIA1): identification and primary structure of the cholesterol binding region in cytochrome P-450SCC. Biochim Biophys Acta. 1993;1161:124-130.
54. Proksch E, Feingold KR, Elias PM. Epidermal HMG CoA reductase activity in essential fatty acid deficiency: barrier requirements rather than eicosanoid generation regulate cholesterol synthesis. J Invest Dermatol. 1992;99:216-220.
55. Helmuth L. Neuroscience: pesticide causes Parkinson's in rats. Science. 2000;290:1068.
56. Ritz B, Yu F. Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int J Epidemiol. 2000;29:323-329.
57. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology. 1993;43:1693-1697.
58. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology. 1992;42:1328-1335.
59. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000;3:1301-1306.
60. Blasiak J, Walter Z. Protective action of cholesterol against changes in membrane fluidity induced by malathion. Acta Biochim Pol. 1992;39:49-52.
61. Li W-F, Costa L, Furlong C. Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health. 1993;40:337-346.
62. Costa LG, McDonald BE, Murphy SD, et al. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol. 1990;103:66-76.
63. Costa LG, Richter RJ, Murphy SD, Omenn GS, Motulsky AG. Species differences in serum paraoxonase activity correlate with sensitivity to paraoxon toxicity. In: Costa L, Galli C, Murphy S, eds. Toxicology of Pesticides: Experimental, Clinical, and Regulatory Aspects. Berlin, Germany: Springer-Verlag; 1987:263-266. NATO ASI series, vol H13.
64. Mutch E, Blain PG, Williams FM. Interindividual variations in enzymes controlling organophosphate toxicity in man. Hum Exp Toxicol. 1992;11:109-116.
65. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol. 1997;122:265-268.
66. Fricker RD, Reardon E, Spektor DM, et al. A Review of the Scientific Literature as It Pertains to Gulf War Illnesses, Volume 12: Pesticide Use During the Gulf War: A Survey of Gulf War Veterans. Santa Monica, Calif: RAND; 2000. MR-1018/12-OSD.
67. Cherry N, Mackness M, Durrington P, et al. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet. 2002;359:763-764.
68. Haley RW, Billecke S, la Du BN. Association of low PON1 type Q (type A) arylesterase activity with neurological symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol. 1999;157:227-233.
69. Mackness B, Durrington PN, Mackness MI. Low paraoxonase in Persian Gulf War veterans self-reporting Gulf War syndrome. Biochem Biophys Res Commun. 2000;276:729-733.
70. Furlong CE. PON1 status and neurologic symptom complexes in Gulf War veterans. Genome Res. 2000;10:153-155.
71. Weverling-Rignsburger A, Blauw G, Lagaay A, Knook D, Meinders A, Westendorp R. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997;350:1119-1123.
72. Roth T, Richardson GR, Sullivan JP, Lee RM, Merlotti L, Roehrs T. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol. 1992;15:426-432.
73. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108:538-546.
74. Velussi M, Cernigoi AM, Tortul C, Merni M. Atorvastatin for the management of type 2 diabetic patients with dyslipidaemia: a mid-term (9 months) treatment experience. Diabetes Nutr Metab. 1999;12:407-412.
75. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000;35:549-555.
76. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34:1281-1286.
77. Marumo H, Satoh K, Yamamoto A, Kaneta S, Ichihara K. Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats. Yakugaku Zasshi. 2001;121:761-764.
78. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol. 1999;83:1497-1499, A8.
79. Furberg CD. Natural statins and stroke risk. Circulation. 1999;99:185-188.
80. Boshuizen HC, Izaks GJ, van Buuren S, Ligthart GJ. Blood pressure and mortality in elderly people aged 85 and older: community based study. BMJ. 1998;316:1780-1784.
81. Guo Z, Viitanen M, Fratiglioni L, Winblad B. Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ. 1996;312:805-808.
82. Kannel WB, D'Agostino RB, Silbershatz H. Blood pressure and cardiovascular morbidity and mortality rates in the elderly. Am Heart J. 1997;134:758-763.
83. Langer RD, Ganiats TG, Barrett-Connor E. Paradoxical survival of elderly men with high blood pressure. BMJ. 1989;298:1356-1357.
84. Langer RD, Ganiats TG, Barrett-Connor E. Factors associated with paradoxical survival at higher blood pressures in the very old [published correction appears in Am J Epidemiol. 1993;138:774]. Am J Epidemiol. 1991;134:29-38.
85. Langer RD, Ganiats TG, Barrett-Connor E. Factors associated with paradoxical survival at higher blood pressures in the very old [published correction appears in Am J Epidemiol. 1993;138:774]. Am J Epidemiol. 1991;134:29-38.
86. Langer RD, Criqui MH, Barrett-Connor EL, Klauber MR, Ganiats TG. Blood pressure change and survival after age 75. Hypertension. 1993;22:551-559.
87. Lee ML, Rosner BA, Weiss ST. Relationship of blood pressure to cardiovascular death: the effects of pulse pressure in the elderly. Ann Epidemiol. 1999;9:101-107.
88. M'Buyamba-Kabangu JR, Longo-Mbenza B, Tambwe MJ, Dikassa LN, Mbala-Mukendi M. J-shaped relationship between mortality and admission blood pressure in black patients with acute stroke. J Hypertens. 1995;13:1863-1868.
89. Paterniti S, Verdier-Taillefer MH, Geneste C, Bisserbe JC, Alperovitch A. Low blood pressure and risk of depression in the elderly: a prospective community-based study. Br J Psychiatry. 2000;176:464-467.
90. Vatten LJ, Holmen J, Kruger O, Forsen L, Tverdal A. Low blood pressure and mortality in the elderly: a 6-year follow-up of 18,022 Norwegian men and women age 65 years and older. Epidemiology. 1995;6:70-73.
91. Kario K, Motai K, Mitsuhashi T, et al. Autonomic nervous system dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation: relation to silent cerebrovascular disease. Hypertension. 1997;30:1504-1510.
92. Watanabe N, Imai Y, Nagai K, et al. Nocturnal blood pressure and silent cerebrovascular lesions in elderly Japanese. Stroke. 1996;27:1319-1327.
93. Nedostup AV, Fedorova VI, Dmitriev KV. Labile hypertension in elderly: clinical features, autonomic regulation of circulation, approaches to treatment [in Russian]. Klin Med (Mosk). 2000;78:27-32.
94. King DS, Jones EW, Wofford MR, et al. Cognitive impairment associated with atorvastatin [abstract]. Pharmacotherapy. 2001;21:371. Abstract 36.
95. Graedon J, Graedon T. The people's pharmacy: can low cholesterol cause confusion? Available at: http://healthcentral.com/peoplespharmacy/pharmfulltext .cfm?ID=36572&storytype=PPherbdrug. Accessed June 19, 2000.
96. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19:26-37.
97. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994;34:989-996.
98. Yamazaki M, Tokui T, Ishigami M, Sugiyama Y. Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. Biopharm Drug Dispos. 1996;17:775-789.
99. Yamazaki M, Kobayashi K, Sugiyama Y. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinaemic rats [published correction appears in Biopharm Drug Dispos. 1997;18:i]. Biopharm Drug Dispos. 1996;17:645-659.
100. Yamazaki M, Kobayashi K, Sugiyama Y. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinaemic rats [published correction appears in Biopharm Drug Dispos. 1997;18:i]. Biopharm Drug Dispos. 1996;17:645-659.
101. Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res. 1996;13:1559-1564.
102. Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther. 2001;297:861-867.
103. Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology. 1996;34:51-61.
104. Sirtori CR. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol Ther. 1993;60:431-459.
105. Pan HY. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol. 1991;40(suppl 1):S15-S18.
106. Golomb BA. Cholesterol and violence: is there a connection? Ann Intern Med. 1998;128:478-487.
107. Jacobs D, Blackburn H, Higgins M, et al. Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation. 1992;86:1046-1060.
108. Neaton J, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med. 1992;152:1490-1500.
109. Lindberg G, Rastam L, Gullberg B, Eklund G. Low serum cholesterol concentration and short term mortality from injuries in men and women. BMJ. 1992;305:277-279.
110. Partonen T, Haukka J, Virtamo J, Taylor PR, Lonnqvist J. Association of low serum total cholesterol with major depression and suicide. Br J Psychiatry. 1999;175:259-262.
111. Zurelk M, Courbon D, Ducimetiere P. Serum cholesterol concentration and death from suicide in men: Paris prospective study I. BMJ. 1996;313:649-650.
112. Hansenne M, Ansseau M. Harm avoidance and serotonin. Biol Psychol. 1999;51:77-81.
113. Hansenne M, Pitchot W, Moreno AG, et al. Harm avoidance dimension of the tridimensional personality questionnaire and serotonin-IA activity in depressed patients. Biol Psychiatry. 1997;42:959-961.
114. Nelson EC, Cloninger CR, Przybeck TR, Csernansky JG. Platelet serotonergic markers and tridimensional personality questionnaire measures in a clinical sample. Biol Psychiatry. 1996;40:271-278.
115. Tanskanen A, Vartiainen E, Tuomilehto J, Viinamaki H, Lehtonen J, Puska P. High serum cholesterol and risk of suicide. Am J Psychiatry. 2000;157:648-650.
116. Tanskanen A, Tuomilehto J, Viinamaeki H. Cholesterol, depression and suicide. Br J Psychiatry. 2000;176:398-399.
117. Golomb BA, Stattin H, Mednick SA. Low cholesterol and violent crime. J Psychiatr Res. 2000;34:301-309.
118. Hillbrand M, Foster H, Hirt M. Variables associated with violence in a forensic population. J Interpers Violence. 1988;3:371-380.
119. Gallerani M, Manfredini R, Caracciolo S, Scapoli C, Molinari S, Fersini C. Serum cholesterol concentrations in parasuicide. BMJ. 1995;310:1632-1636.
120. Golier JA, Marzuk PM, Leon AC, Weiner C, Tardiff K. Low serum cholesterol level and attempted suicide. Am J Psychiatry. 1995;152:419-423.
121. Sullivan P, Joyce P, Bulik C, Mulder R, Oakley-Browne M. Total cholesterol and suicidality in depression. Biol Psychiatry. 1994;38:472-477.
122. Modai I, Valevski A, Dror S, Weizman A. Serum cholesterol levels and suicidal tendencies in psychiatric inpatients. J Clin Psychiatry. 1994;55:252-254.
123. Takei N, Kunugi H, Nanko S, Aoki H, Iyo R, Kazamatsuri H. Low serum cholesterol and suicide attempts. Br J Psychiatry. 1994;164:702-703.
124. Hillbrand M, Foster H. Serum cholesterol levels and severity of aggression [abstract]. Psychol Rep. 1993;72:270.
125. Hillbrand M, Spitz R, Foster H. Serum cholesterol and aggression in hospitalized male forensic patients. J Behav Med. 1995;18:33-43.
126. Virkkunen M. Serum cholesterol in antisocial personality. Neuropsychobiology. 1979;5:27-30.
127. Virkkunen M. Serum cholesterol levels in homicidal offenders: a low cholesterol level is connected with a habitually violent tendency under the influence of alcohol. Neuropsychobiology. 1983;10:65-69.
128. Virkkunen M, Penttinen H. Serum cholesterol in aggressive conduct disorder: a preliminary study. Biol Psychiatry. 1984;19:435-439.
129. Spitz R, Hillbrand M, Foster HJ. Serum cholesterol levels and frequency of aggression. Psychol Rep. 1994;74:622.
130. Mufti R, Balon R, Arfken C. Low cholesterol and violence. Psychiatr Serv. 1998;49:221-224.
131. Kaplan J, Manuck S. The effects of fat and cholesterol on aggressive behavior in monkeys. Psychosom Med. 1990;52:226-227.
132. Kaplan JR, Shively C, Fontenot D, et al. Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behavior in monkeys. Psychosom Med. 1994;56:479-484.
133. Kaplan JR, Fontenot MB, Manuck SB, Muldoon MF. An inverse association between dietary lipids and agonistic and affiliative behavior in Macaca fascicularis. Am J Primatol. 1996;38:333-347.
134. Bramblett C, Coelho A, Mott G. Behavior and serum cholesterol in a social group of cercopithecus aethiops. Primates. 1981;22:96-102.
135. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ. 1992;304:431-434.
136. Muldoon M, Manuck S, Matthews K. Lowering cholesterol concentrations and mortality: a review of primary prevention trials. BMJ. 1990;301:309-314.
137. Muldoon M, Rossouw J, Manuck S, Gluech C, Kaplan J, Kaufmann P. Low or lowered cholesterol and risk of death from suicide and trauma. Metabolism. 1993;42:45-56.
138. Law M, Thompson S, Wald N. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308:373-379.
139. Cummings P, Psaty B. The association between cholesterol and death from injury. Ann Intern Med. 1994;120:848-855.
140. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ. 1992;305:15-19.
141. Wysowski D, Gross T. Deaths due to accidents and violence in two recent trials of cholesterol-lowering drugs. Arch Intern Med. 1990;150:2169-2172.
142. Stein JH, McBride PE. Benefits of cholesterol screening and therapy for primary prevention of cardiovascular disease: a new paradigm. J Am Board Fam Pract. 1998;11:72-77.
143. Anderson I, Parry-Billings M, Newsholme E. Dieting reduces plasma tryptophan and alters brain 5-HT function in women. Psychol Med. 1990;20:785-791.
144. Muldoon M, Kaplan J, Manuck S, Mann J. Effects of a low-fat diet on brain serotonergic responsivity in cynomolgus monkeys. Biol Psychiatry. 1992;31:739-742.
145. Ringo D, Lindley S, Faull K, Faustman W. Cholesterol and serotonin: seeking a possible link between blood cholesterol and CSF 5-HIAA. Biol Psychiatry. 1994;35:957-959.
146. Delva N, Matthews D, Cowen P. Brain serotonin (5-HT) neuroendocrine function in patients taking cholesterol-lowering drugs. Biol Psychiatry. 1996;39:100-106.
147. Steegmans P, Fekkes D, Hoes A, Bak A, van der Does E, Grobbee D. Low serum cholesterol concentration and serotonin metabolism in men [letter]. BMJ. 1996;312:221.
148. Golomb BA, Tenkanen L, Alikoski T, et al. Insulin sensitivity markers: predictors of accidents and suicides in Helsinki Heart Study screenees. J Clin Epidemiol. 2002;55:1-7.
149. Coccaro E. Central serotonin and impulsive aggression. Br J Psychiatry Suppl. December 1989;(8):52-62.
150. Brown G, Goodwin F, Ballenger J, Goyer P, Major L. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res. 1979;1:131-139.
151. Brown G, Linnoila M. CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. J Clin Psychiatry. 1990;51:31-41.
152. Asberg M. Neurotransmitters and suicidal behavior: the evidence from cerebrospinal fluid studies. Ann N Y Acad Sci. 1997;836:158-181.
153. Gibbons J, Barr G, Bridger W, Liebowitz S. Manipulations of dietary tryptophan: effects on mouse killing and brain serotonin in the rat. Brain Res. 1979;169:139-153.
154. Kantak KM, Hegstrand LR, Eichlman B. Dietary tryptophan modulation and aggressive behavior in mice. Pharmacol Biochem Behav. 1980;12:675-679.
155. Kantak KM, Hegstrand LR, Eichelman B. Dietary tryptophan reversal of septal lesion and 5,7-DHT lesion elicited shock-induced fighting. Psychopharmacology. 1981;74:157-160.
156. Sheard M, Davis M. p-Chloroamphetamine: short and long term effects upon shock-elicited aggression. Eur J Pharmacol. 1976;40:295-302.
157. Gibbons J, Barr G, Bridger W. Effects of parachlorophenylalanine and 5-hydroxytryptophan on mouse killing behavior in killer rats. Pharmacol Biochem Behav. 1978;9:91-98.
158. Grant L, Coscina D, Grossman S, Freedman D. Muricide after serotonin-depleting lesions of midbrain raphe nuclei. Pharmacol Biochem Behav. 1973;1:77-80.
159. Yamamoto T, Ueki S. Characteristics in aggressive behavior induced by midbrain raphe lesions in rats. Physiol Behav. 1977;19:105-110.
160. Paxinos G, Burt J, Atrens D, Jackson D. 5-Hydroxytryptamine depletion with para-chlorophenylalanine: effects on eating, drinking, irritability, muricide, and copulation. Pharmacol Biochem Behav. 1977;6:439-447.
161. Paxinos G, Atrens D. 5,7 Dihydroxytryptamine lesions: effects on body weight, irritability and muricide. Aggress Behav. 1977;3:107-118.
162. Saudou R, Amara D, Dierich A, et al. Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science. 1994;265:1875-1878.
163. Miczek K, Weerts E, Haney M, Tidey J. Neurobiological mechanisms controlling aggression: preclinical developments for pharmacotherapeutic interventions. Neurosci Biobehav Rev. 1994;18:97-110.
164. Blanchard D, Rodgers R, Hendrie C, Hori K. "Taming" of wild rats (Rattus rattus) by 5HT1A agonists buspirone and gepirone. Pharmacol Biochem Behav. 1988;31:269-278.
165. Berzsenyi P, Galateo E, Valzelli L. Fluoxetine activity of muricidal aggression induced in rats by p-chlorophenylalanine. Aggress Behav. 1983;9:333-338.
166. Åsberg M. Monoamine neurotransmitters in human aggressiveness and violence: a selective review. Criminal Behav Mental Health. 1994;4:303-327.
167. Mann J, Arango A, Marzuk P, Theccanat S, Reis DJ. Evidence for the 5-HT hypothesis of suicide: a review of post-mortem studies. Br J Psychiatry Suppl. December 1989;(8):7-14.
168. Lidberg L, Åsberg M, Sundquist-Stensman U. 5-Hydroxyindoleacetic acid in attempted suicides who kill their children [letter]. Lancet. 1984;2:928.
169. Lidberg L, Tuck J, Åsberg M, Scalia-Tomba G, Bertilsson L. Homicide, suicide and CSF 5HIAA. Acta Psychiatr Scand. 1985;71:230-236.
170. Gedye A. Buspirone alone or with serotonergic diet reduced aggression in a developmentally disabled adult. Biol Psychiatry. 1991;30:88-91.
171. Ratey J, Sovner R, Parks A, Rogentine K. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. J Clin Psychiatry. 1991;52:159-162.
172. Morand C, Young SN, Ervin FR. Clinical response of aggressive schizophrenics to oral tryptophan. Biol Psychiatry. 1983;18:575-578.
173. Bioulac B, Benezech M, Renaud B, Roche D, Noel B. Biogenic amines in 47,XYY syndrome. Neuropsychopharmacology. 1978;4:366-370.
174. Bioulac B, Benezech M, Renaud B, Noel B, Roche D. Serotonergic dysfunction in the 47,XYY syndrome. Biol Psychiatry. 1980;15:917-923.
175. Sheard M, Marini J, Bridges C. The effect of lithium on impulsive aggression behavior in man. Am J Psychiatry. 1976;133:1409-1413.
176. Raine A. Autonomic nervous system activity and violence. In: Stoff D, Cairns R, eds. Aggression and Violence: Genetic, Neurobiological, and Biosocial Perspectives. Mahwah, NJ: Lawrence Erlbaum Associates Inc; 1996:145-168.
177. Raine A. Autonomic nervous system factors underlying disinhibited, antisocial, and violent behavior: biosocial perspectives and treatment implications. Ann N Y Acad Sci. 1996;794:46-59.
178. Pitts T. Reduced heart rate levels in aggressive children. In: Adrian Raine AE, Brennan P, Farrington DP, eds. Biosocial Bases of Violence. New York, NY: Plenum Press; 1997:317-320.
179. Gottman J, Jacobson N, Rushe R, Shortt J. The relationship between heart rate reactivity, emotionally aggressive behavior, and general violence in batterers. J Fam Psychol. 1995;9:227-248.
180. Scarpa A, Raine A. Psychophysiology of anger and violent behavior. Psychiatr Clin North Am. 1997;20:375-394.
181. Woodman D, Hinton J, O'Neill M. Relationship between violence and catecholamines [abstract]. Percept Mot Skills. 1977;45:702.
182. Woodman D, Hinton J, O'Neill M. Plasma catecholamines, stress and aggression in maximum security patients. Biol Psychol. 1978;6:147-154.
183. Woodman D, Hinton J. Catecholamine balance during stress anticipation: an abnormality in maximum security hospital patients. J Psychosom Res. 1978;22:477-483.
184. Brenneman D, Rutledge C. Alteration of catecholamine uptake in cerebral cortex from rats fed a saturated fat diet. Brain Res. 1979;179:295-304.
185. Broderick R, Bialecki R, Tulenko T. Cholesterol-induced changes in rabbit arterial smooth muscle sensitivity to adrenergic stimulation. Am J Physiol. 1989;257:H170-H178.
186. McMurchie E, Parten G, Charnock J, McLennan P. The interaction of dietary fatty acids and cholesterol on catecholamine-stimulated adenylate cyclase activity in the rat heart. Biochem Biophys Acta. 1987;898:137-153.
187. McMurchie E, Patten G. Dietary cholesterol influences cardiac beta-adrenergic receptor adenylate cyclase activity in the marmoset monkey by changes in membrane cholesterol status. Biochem Biophys Acta. 1988;942:324-332.
188. Vogele C. Serum lipid concentrations, hostility and cardiovascular reactions to mental stress. Int J Psychophysiol. 1998;28:167-179.
189. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
190. Davey Smith G, Song F, Sheldon T. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993;306:1367-1373.
191. Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis. 1993;101:117-125.
192. Corsini A, Arnaboldi L, Quarato P, et al. Pharmacological control of biosynthesis pathway of mevalonate: effect on the proliferation of arterial smooth muscle cells [in French]. C R Seances Soc Biol Fil. 1997;191:169-194.
193. Corsini A, Arnaboldi L, Raiteri M, et al. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res. 1996;33:55-61.
194. Corsini A, Bernini F, Quarato P, et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology. 1996;87:458-468.
195. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res. 1995;31:9-27.
196. Corsini A, Pazzucconi F, Pfister P, Paoletti R, Sirtori CR. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin [letter]. Lancet. 1996;348:1584.
197. Chilton RJ. Lipid and nonlipid benefits of statins. J Am Osteopath Assoc. 2003;103(7, suppl 3):S12-S17.
198. Hernandez-Presa M, Bustos C, Oertega M, et al. Atorvastatin abolishes macrophage infiltration and reduces neointimal formation and MCP-1 expression in a rabbit model of atherosclerosis: role of nuclear factor kB. Circulation. 1997;96(suppl):1-291.
199. Laufs U, Plutzky J, Liao J. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1997;96:1-677.
200. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet. 1997;32:403-425.
201. Leonhardt W, Kurktschiev T, Meissner D, et al. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals. Eur J Clin Pharmacol. 1997;53:65-69.
202. Raiteri M, Arnaboldi L, Quarato P, Paoletti R, Fumagalli R, Corsini A. The pharmacology of the statins: the evidence of a direct antiatherosclerotic action [in Italian]. Ann Ital Med Int. 1995;10(suppl):35S-42S.
203. Massy Z, Keane W, Kasiske B. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet. 1996;347:102-103.
204. Mitani H, Bandoh T, Ishikawa J, Kimura M, Totsuka T, Hayashi S. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol. 1996;119:1269-1275.
205. Mitropoulos KA, Armitage JM, Collins R, et al, Oxford Cholesterol Study Group. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. Eur Heart J. 1997;18:235-241.
206. Reissen R, Fenchel M. HMG-CoA reductase inhibitors alter the expression of extracellular matrix in human vascular smooth muscle cells [abstract]. Circulation. 1997;96(suppl):1-487.
207. Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis. 1996;122:225-233.
208. Williams K, Sukhova G, Anthony M, Libby P. The cholesterol-lowering independent effects of pravastatin on the artery wall of monkeys [abstract]. Circulation. 1997;96(suppl):1-607.
209. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
210. Bradford R, Shear C, Chremos A, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
211. Eckernas SA, Roos BE, Kvidal P, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmacol. 1993;35:284-289.
212. Kamei Y, Shirakawa S, Ishizuka Y, et al. Effect of pravastatin on human sleep. Jpn J Psychiatry Neurol. 1993;47:643-646.
213. Buajordet I, Madsen S, Olsen H. Statins-the pattern of adverse effects with emphasis on mental reactions: data from a national and an international database [in Norwegian]. Tidsskr Nor Laegeforen. 1997;117:3210-3213.
214. England JD, Viles A, Walsh JC, Stewart PM. Muscle side effects associated with simvastatin therapy. Med J Aust. 1990;153:562-563.
215. Reust CS, Curry SC, Guidry JR. Lovastatin use and muscle damage in healthy volunteers undergoing eccentric muscle exercise. West J Med. 1991;154:198-200.
216. Flint OP, Masters BA, Gregg RE, Durham SK. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol. 1997;145:99-110.
217. Pierno S, De Luca A, Tricarico D, et al. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther. 1995;275:1490-1496.
218. Sinzinger H, Schmid P, O'Grady J. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-co-enzyme-A-reductase inhibitor treatment. Atherosclerosis. 1999;143:459-460.
219. Sinzinger H. Does vitamin E beneficially affect muscle pains during HMG-Co-A-reductase inhibitors without CK-elevation [letter]? Atherosclerosis. 2000;149:225.
220. England JD, Walsh JC, Stewart P, Boyd I, Rohan A, Halmagyi GM. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors-simvastatin and pravastatin. Aust N Z J Med. 1995;25:374-375.
221. Waclawik AJ, Lindal S, Engel AG, Experimental lovastatin myopathy. J Neuropathol Exp Neurol. 1993;52:542-549.
222. Scalvini T, Marocolo D, Cerudelli B, Sleiman I, Balestrieri GP, Giustina G. Pravastatin-associated myopathy: report of a case. Recenti Prog Med. 1995;86:198-200.
223. Wicher-Muniak E, Zmudka K, Dabros W, Dudek D, Stachura J. Simvastatin-induced myopathy in a patient treated for hypercholesterolemia: morphological aspects. Pol J Pathol. 1997;48:69-74.
224. Schalke BB, Schmidt B, Toyka K, Hartung HP. Pravastatin-associated inflammatory myopathy. N Engl J Med. 1992;327:649-650.
225. Kaikkonen J, Nyyssonen K, Tuomainen TP, Ristonmaa U, Salonen JT. Determinants of plasma coenzyme Q10 in humans. FEBS Lett. 1999;443:163-166.
226. Miyake Y, Shouzu A, Nishikawa M, et al. Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittelforschung. 1999;49:324-329.
227. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18(suppl):S137-S144.
228. McCarty MF. Toward a wholly nutritional therapy for type 2 diabetes. Med Hypotheses. 2000;54:483-487.
229. Kelly GS. Insulin resistance: lifestyle and nutritional interventions. Altern Med Rev. 2000;5:109-132.
230. Danysz A, Oledzka K, Bukowska-Kiliszek M. Influence of coenzyme Q-10 on the hypotensive effects of enalapril and nitrendipine in spontaneously hypertensive rats. Pol J Pharmacol. 1994;46:457-461.
231. Li N, Sawamura M, Nara Y, et al. HMG-CoA reductase inhibitor affects blood pressure and vascular reactivity. Clin Exp Pharmacol Physiol Suppl. 1995;22 (suppl 1):S316-S317.
232. Li N, Sawamura M, Nara Y, Ikeda K, Yamori Y. Pravastatin affects blood pressure and vascular reactivity. Heart Vessels. 1996;11:64-68.
233. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-362.
234. Patterson S, Gottdiener J, Hecht G, Vargot S, Krantz D. Effects of acute mental stress on serum lipids: mediating effects of plasma volume. Psychosom Med. 1993;55:525-532.
235. Muldoon M, Herbert T, Patterson S, Kameneva M, Raible R, Manuck S. Effects of acute psychological stress on serum lipid levels, hemoconcentration, and blood viscosity. Arch Intern Med. 1995;155:615-620.
236. Reifman A, Windle M. High cholesterol levels in patients with panic disorder: comment [letter]. Am J Psychiatry. 1993;150:527.
237. Peter H, Tabrizian S, Hand I. Serum cholesterol in patients with obsessive compulsive disorder during treatment with behavior therapy and SSRI or placebo. Int J Psychiatry Med. 2000;30:27-39.
238. Kuczmierczyk AR, Barbee JG, Bologna NA, Townsend MH. Serum cholesterol levels in patients with generalized anxiety disorder (GAD) and with GAD and comorbid major depression. Can J Psychiatry. 1996;41:465-468.
239. Bajwa WK, Asnis GM, Sanderson WC, Irfan A, van Praag HM. High cholesterol levels in patients with panic disorder. Am J Psychiatry. 1992;149:376-378.
240. Hayward C, Taylor C, Roth W, King R, Agras W. Plasma lipid levels in patients with panic disorder or agoraphobia. Am J Psychiatry. 1989;146:917-919.
241. Kagan BL, Leskin G, Haas B, Wilkins J, Foy D. Elevated lipid levels in Vietnam veterans with chronic posttraumatic stress disorder. Biol Psychiatry. 1999;45:374-377.
242. Golomb BA, Jaworski B. Statins and dementia. Arch Neurol. 2001;58:1169-1170.
243. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia [published correction appears in Lancet, 2001;357:562]. Lancet. 2000;356:1627-1631.
244. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia [published correction appears in Lancet, 2001;357:562]. Lancet. 2000;356:1627-1631.
245. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-1443.